ACADIA Pharmaceuticals (ACAD) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free ACAD Stock Alerts $15.10 +0.10 (+0.67%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 8:40 AM | americanbankingnews.comQ2 2024 Earnings Estimate for ACADIA Pharmaceuticals Inc. Issued By Zacks Research (NASDAQ:ACAD)May 30 at 5:17 AM | marketbeat.com1,443,218 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Norges BankNorges Bank bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,443,218 shares of the biopharmaceutical comMay 29, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 52-Week Low at $14.60ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 12-Month Low at $14.60May 27, 2024 | finanznachrichten.deNeuren Pharmaceuticals Ltd: Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndromeMay 23, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)May 22, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been assigned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and twelve have issued aMay 21, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Acquires New Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Massachusetts Financial Services Co. MA bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 60,564 shares ofMay 20, 2024 | marketbeat.comBridger Management LLC Invests $3.67 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Bridger Management LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 117,341 shares of the biopharmaceutical company's stock, valued at aMay 19, 2024 | marketbeat.comBNP Paribas Financial Markets Decreases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)BNP Paribas Financial Markets lowered its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 24.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 229,765 shares of the biopharmaceutical company's stock after selling 75,403 shaMay 17, 2024 | businesswire.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 17, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Elicio Therapeutics (ELTX)May 15, 2024 | stocknews.com3 Pharma Stocks to Buy for Potential Financial FortunesMay 15, 2024 | marketbeat.comM&G Investment Management Ltd. Acquires New Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)M&G Investment Management Ltd. bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 333,824 shares of the biopharmaceutical companyMay 15, 2024 | businesswire.comAcadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeMay 12, 2024 | marketbeat.comJump Financial LLC Purchases 89,053 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Jump Financial LLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 326.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 116,341 shares of the biopharMay 11, 2024 | markets.businessinsider.comNeutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration ForecastsMay 11, 2024 | finance.yahoo.comResults: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial StabilityMay 10, 2024 | finance.yahoo.comACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $22.00 by Analysts at Bank of AmericaBank of America decreased their price objective on shares of ACADIA Pharmaceuticals from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Friday.May 10, 2024 | marketbeat.comBrokers Set Expectations for ACADIA Pharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Stock analysts at Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceuMay 9, 2024 | marketbeat.comCitigroup Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00Citigroup decreased their price objective on shares of ACADIA Pharmaceuticals from $30.19 to $30.00 and set a "buy" rating for the company in a research report on Thursday.May 9, 2024 | markets.businessinsider.comPositive Buy Rating for ACADIA Pharmaceuticals Amid Solid Market Presence and Underestimated Long-Term OpportunitiesMay 9, 2024 | markets.businessinsider.comMaintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth ProspectsMay 9, 2024 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | businesswire.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 9, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings ResultsACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.06. ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm had revenue of $205.83 million during the quarter, compared to the consensus estimate of $208.31 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. The firm's quarterly revenue was up 73.8% compared to the same quarter last year.May 9, 2024 | marketbeat.comACADIA Pharmaceuticals' (ACAD) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday.May 9, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 12-Month Low Following Analyst DowngradeACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 52-Week Low Following Analyst DowngradeMay 9, 2024 | markets.businessinsider.comACADIA Pharmaceuticals: Strong Sales and Promising Pipeline Justify Buy RatingMay 9, 2024 | finance.yahoo.comACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...May 8, 2024 | investorplace.comACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | seekingalpha.comACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | marketbeat.com143,054 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Fisher Asset Management LLCFisher Asset Management LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 143,054 shMay 7, 2024 | markets.businessinsider.comACADIA Pharmaceuticals is about to announce its earnings — here's what Wall Street expectsMay 6, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Given Market Perform Rating at OppenheimerOppenheimer reissued a "market perform" rating and set a $19.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday.May 5, 2024 | insidertrades.comJames Kihara Sells 1,326 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 5, 2024 | insidertrades.comBrendan Teehan Sells 3,477 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 4, 2024 | finance.yahoo.comInsider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)May 2, 2024 | stocknews.comBuy Alert: 3 Pharma Stocks Under $20 to Invest in NowMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Sarepta Therapeutics (SRPT) and Acadia Healthcare (ACHC)May 1, 2024 | finance.yahoo.comNewron’s add-on schizophrenia therapy finds success in Phase II/III trialMay 1, 2024 | marketbeat.comACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on WednesdayACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589710)April 30, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)April 30, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)Cantor Fitzgerald restated an "overweight" rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday.April 29, 2024 | businesswire.comAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipApril 28, 2024 | finance.yahoo.comACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years agoApril 27, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and twelve have assigned a buy recoApril 24, 2024 | businesswire.comAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024April 23, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 52-Week Low at $16.60ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 12-Month Low at $16.60 Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. ACAD Media Mentions By Week ACAD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.380.76▲Average Medical News Sentiment ACAD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼86▲ACAD Articles Average Week Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bausch Health Companies News Mirati Therapeutics News Catalent News Roivant Sciences News Elanco Animal Health News Legend Biotech News Cerevel Therapeutics News Ascendis Pharma A/S News Viking Therapeutics News Insmed News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
